This study provides initial data on mCRPC patients undergoing therapy with Zytiga (abiraterone/prednisone) and suggests that the efficacy may not be compromised if LHRH therapy (such as Lupron or Firmagon) is discontinued. The primary endpoint of this study was radiographic progression-free survival (rPFS) at 1 year and there was no significant difference between the 2 arms. It was a small study with just 67 patients. To read the full ASCO Conference summary written by Jason Zhu, MD., Duke University, click here: http://tiny.cc/fs9w7y
Forum Login
Forum Registration
Password Reset
Categories
Recent Posts
Tags
'end-of-life'
active surveillance
ADT
advanced PCa
advanced PCa recorded group
advanced prostate cancer
advanced prostate cancer virtual support
Advocacy
AnCan
blood cancers
Brain Tumors
Breast Cancer
cancer
Cancer Caregivers
Cancer resource
cancer survivor
Courage
Exercise
exercise on ADT
Ga68 PSMA
high risk
hospice and palliative
Lu177 PSMA
male breast cancer
mCRPC
Men's Breast Cancer
Metastatic Prostate Cancer
MS
multiple sclerosis
Ovarian Cancer
Pluvicto
Prostate Cancer
PSMA
recurrent
Renal Medullary Carcinoma
RMC
sarcoidosis
screening for recurrent prostate cancer
Strength
thyroid cancer
u-60 Advanced Prostate Cancer
UsTOO Virtual Support Group
virtual prostate cancer support groups
Virtual Support Groups
Webinars